According to a recent speech by Scott Gottlieb, MD, the current FDA commissioner, today’s FDA is committed to expediting development of breakthrough drugs and is in favor of more rapid and less costly development programs. Thanks to the efforts of Wiley Chambers, MD, Malvina Eydelman, MD, and their teams charged with approving new ophthalmic drugs and devices, 2017 and 2018 in the field of ophthalmology were banner years. While hematology, oncology, and rare and orphan drugs represented the highest number of approvals, ophthalmology was well represented.
If and when it (Read more...)
Uncategorized